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Purpose: The incidence of esophageal adenocarcinoma (EAC) has increased by 700% in
Western countries over the last 30 years. Although clinical guidelines call for endoscopic
surveillance for EAC among high-risk populations, fewer than 5% of new EAC patients are
under surveillance at the time of diagnosis. We studied the accuracy of combined cytopathol-
ogy and MUC2 immunohistochemistry (IHC) for screening of Intestinal Metaplasia (IM),
dysplasia and EAC, using specimens collected from the EsophaCap swallowable encapsu-
lated cytology sponge from Canada and United States.
Patients and methods: By comparing the EsophaCap cytological diagnosis with concur-
rent endoscopic biopsies performed on the same patients in 28 cases, we first built up the
cytology diagnostic categories and criteria. Based on these criteria, 136 cases were evaluated
by both cytology and MUC2 IHC with blinded to patient biopsy diagnosis.
Results: We first set up categories and criteria for cytological diagnosis of EscophaCap
samples. Based on these, we divided our evaluated cytological samples into two groups: non-
IM group and IM or dysplasia or adenocarcinoma group. Using the biopsy as our gold
standard to screen IM, dysplasia and EAC by combined cytology and MUC2 IHC, the
sensitivity and specificity were 68% and 91%, respectively, which is in the range of clinically
useful cytological screening tests such as the cervical Pap smear.
Conclusions: Combined EsophaCap cytology and MUC2 IHC could be a good screening
test for IM and Beyond.
Keywords: Barrett’s esophagus, esophageal adenocarcinoma, cytology screening, MUC2
IHC, EsophaCap, intestinal metaplasia
Introduction
The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western
countries, having increased 6–7 folds in North America since the 1980s.1 EAC is
a devastating disease that carries an overall 5-year survival of only 18–22%.2 Part
of the reason for EAC’s poor prognosis is that most patients present at an advanced
stage when they experience obstructive symptoms such as discomfort on swallow-
ing. The single major risk factor for the development of EAC is Barrett’s esophagus
(BE), a metaplastic condition in which intestinal-like glandular epithelium replaces
the normal squamous mucosa of the esophagus. BE is a consequence of chronic
gastroesophageal reflux disease (GERD).3,4 Roughly 15–40% of the adults in
western countries have GERD, while 8–20% of the GERD adults develop BE.5,6
Patients with BE have between a 0.12% and 0.5% annual rate of progression to
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EAC, and an 11.3–40-fold increase in their lifetime risk of
developing EAC in comparison to the non-BE
population.7–10
In most western countries, clinical guidelines recom-
mend that patients with chronic GERD obtain a baseline
endoscopy to diagnose BE.11,12 Patients with BE are then
recommended to undergo periodic endoscopic surveillance
with biopsy to detect progression to dysplasia and
EAC.11,12 However, in practice endoscopic surveillance
of patients with BE requires loss of a partial work day
for the patient, involves sedation and has a low but real
complication rate.13–15 For these reasons, many patients
and their providers are reluctant to commit to endoscopy.
Furthermore, endoscopy is expensive in comparison to
other screening technologies such as mammography, and
its cost-effectiveness is in doubt.14 Consequently, just 5%
population that is thought to have BE is under
surveillance.7,16–19 Therefore, there is an urgent need to
develop new methods to screen patients with GERD for
BE and to surveil BE patients for progression.
Esophageal balloon cytology has been used in China to
screen for esophageal squamous cell carcinoma19–22 and in
the USA to detect esophageal carcinoma.23,24 Non-
endoscopic screening methods based on swallowable
encapsulated sponges have been developed in the United
Kingdom,25–27 Switzerland28 and in the USA. These tests
are administered in the form of a sponge-containing gela-
tin capsule attached to a string or tether that the patient
swallows like a pill. The sponge expands after swallowing
and is then retrieved with the tether. During retrieval, the
sponge scrapes the esophageal mucosa, collecting epithe-
lial cells for further cytological, immunohistochemical or
genetic analysis. In several large studies, swallowable
encapsulated sponges were well accepted by patients
enrolled in BE surveillance programs.27,29,30 Fitzgerald’s
group in the UK has reported IM detection using trefoil
factor 3 (TFF3) immunohistochemistry on cell blocks
obtained via the Cytosponge™ sampling. The overall sen-
sitivity of the test was 79.9%, increasing to 87.2% for
patients with ≥3 cm of circumferential intestinal metapla-
sia (IM).25 However, the accuracy of swallowable encap-
sulated sponges for the detection of dysplasia and/or
cancer by combined cytopathology and immunohisto-
chemistry has not been reported.
In the current study, we used EsophaCap™ sampling to
obtain esophageal cytology specimens at two North
American sites (Canada and the USA) from 169 patients
with known GERD, BE or dysplasia undergoing routine
endoscopic examination. The sponge cytology specimens
were examined cytologically alone and in combination
with MUC2 immunohistochemistry (IHC). The sensitivity,
specificity and accuracy of these methods for detecting
intestinal metaplasia, dysplasia and EAC were analyzed.
Materials and methods
Patient recruitment and demographics
We recruited adult (18+) patients with previously docu-
mented gastroesophageal reflux disease, BE, or low- or
high-grade dysplasia undergoing routine surveillance,
diagnostic and/or therapeutic endoscopy at either the
St. Michael’s Hospital Endoscopy Unit in Toronto,
Canada (159 patients), or the Boston University in
Boston, MA, USA (10 patients). We excluded subjects
for whom esophageal biopsy or sponge sampling would
be contraindicated, such as those with known esophageal
strictures. Patients gave written informed consent to parti-
cipate in the study, and this study was conducted in accor-
dance with the Declaration of Helsinki. The research
ethics committees approved the study at all clinical and
research sites.
As of September 2016, 250 patients were recruited at
St. Michael’s hospital and Boston University Medical
Centre. Six patients elected not to attempt to swallow
(2.4%). Seventy-five patients tried but were not able to
swallow (30%). One hundred and sixty-nine esophageal
cytology specimens were collected. The major complaint
was gagging, reported by 65% of the patients able to
swallow.
The patient cohort included 80% males and 20%
females with a mean age of 65.8 years. The vast majority
of the studied patients were white (96%) and had a history
of current or past cigarette smoking (72%).
Esophageal cytology collection
The EsophaCap(™) is a gelatin capsule containing
a compressed sponge attached to a tether (Figure 1).
We purchased EsophaCaps(™) from Capnostics LLC
(Doylestown PA). Esophageal cytology samples were
collected by a registered nurse prior to sedation for
endoscopy. The patient swallowed the capsule with
a drink of water while holding the tether loosely. In
5 mins after allowing the capsule to dissolve in the
proximal stomach, it released a spherical polyurethane
sponge in two sizes, 2.5 cm and 3.0 cm in diameter. The
back of the throat was then sprayed with 1% lidocaine
(lignocaine) and the expanded sponge was then
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withdrawn by pulling on the tether. After sponge retrie-
val, the tether was cut and the sponge containing the
cytological specimen was placed in preservative fluid
(CytoLyt) and kept refrigerated prior to transport to the
University of Rochester Pathology department for cytol-
ogy processing.
Endoscopy and biopsy
Subsequent to sponge cytology collection, typically within
1 hr, patients underwent routine endoscopic examination
with biopsy sampling. The biopsies were processed and
examined at the Surgical Pathology units at St. Michael’s
Hospital and Boston University for routine diagnosis. The
first 28 biopsy slides were then transmitted to the
University of Rochester for review by the study GI pathol-
ogist (ZZ). The rest of the biopsy cases were diagnosed by
local GI pathologists.
Cytopathology sample preparation
All specimens were preserved in CytoLyt solution and
processed on the Thin Prep Processor (ThinPrep 2000,
HOLOGIC, MA) using the standard Non-Gyn protocol.
Cell blocks were prepared as follows: the specimen was
centrifuged to produce a concentrated cell button (5 min/
349 g) that was resuspended in 5 ml buffered formalin and
centrifuged again (5 min/349 g) to produce a fixed cell
button. The cell button was then paraffin embedded and
sectioned. Two unstained slides were cut for each sample.
One slide was stained with hematoxylin and eosin, and the
other was sent for MUC2 IHC. All ThinPrep slides and
cell blocks were submitted for cytopathology (ZZ) and
senior cytotechnologist (D. Russell) review.
Cytopathology diagnostic criteria and categories
Based on our review of the first 28 paired cases and
previous cytological classification systems for the
esophagus,31,32 we developed criteria and categories to
classify the glandular cells observed in the ThinPrep and
cell block samples (Table 1). Based on the morphological
criteria, 136 cases were evaluated by one cytopathologist
and one senior cytotechnologist, both blinded to patient
information and the paired biopsy diagnosis. The number
of all glandular cells and squamous cells were counted.
Histologic study of FFPE biopsy specimens
All biopsies were reviewed by gastrointestinal pathologists
in St. Michael hospital and Boston Medical Center. The
new definition for BE by American College of
Gastroenterology is “BE should be diagnosed when there
is an extension of salmon-colored mucosa into the tubular
esophagus extending ≥1 cm proximal to the gastroesopha-
geal junction (GEJ) with biopsy confirmation of intestinal
metaplasia. (IM)”11 Since the length of mucosa is required
for the diagnosis of BE. The pathology cannot directly
diagnose the BE instead of intestinal metaplasia (IM).
The histologic diagnoses were categorized into six cate-
gories (see Table 1) including normal squamous epithe-
lium (SE), columnar cell metaplasia (CM), intestinal
metaplasia (IM), indefinite dysplasia (ID), low-grade dys-
plasia (LGD), high-grade dysplasia (HGD) and EAC.
Based on ACG guideline for BE, BE should be diagnosed
when there is extension of salmon-colored mucosa into the
tubular esophagus extending ≥1 cm proximal to the gastro-
esophageal junction with biopsy confirmation of IM.11
Therefore, our diagnosis from pathology biopsy has to be
A B
Figure 1 EsophaCap is an encapsulated sponge (A) attached to a tether (B).
Dovepress Zhou et al











































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
changed to IM instead of BE. The histological diagnosis
was executed independently from the cytological diagno-
sis. Five cytology cases did not have matched biopsy
diagnosis, which were excluded from the statistics.
Construction of tissue microarray. MUC2 immunostain
was evaluated by tissue microarrays (TMA) that included
33 cases of BE, 64 cases of CM, 95 cases of SE, 31 cases
of LGD, 8 cases of HGD and 109 cases of EAC were
constructed from the representative areas of FFPE speci-
mens collected between 1997 and 2005 at the Department
of Pathology and Laboratory Medicine, University of
Rochester Medical Center, New York. Five-micron sec-
tions were cut from the tissue microarrays and were
stained with H&E to confirm the presence of the expected
tissue histology within each tissue core. Additional sec-
tions were cut for MUC2 IHC.
MUC2 IHC on cell blocks and TMA
Tissue sections from the cell block and esophageal TMA
were deparaffinized, rehydrated through graded alcohols,
and washed with phosphate buffered saline. Antigen retrie-
val was performed by heating sections in 99°C water bath
for 30–40 mins. After endogenous peroxidase activity was
quenched and nonspecific binding was blocked, antibody
for MUC2 (DAKO, CA) was incubated at room tempera-
ture for 30 mins. The secondary antibody (Flex HRP,
DAKO, CA) was allowed to incubate for 30 mins. After
washing, sections were incubated with Flex DAB
Chromogen for 10 mins and counterstained with Flex
Hematoxylin for 5 mins. A previously diagnosed BE
case served as a positive control. Negative control was
performed by replacing antibodies with normal serum.
Data analysis. Summary data are expressed as the means
(SDs). All statistical tests are two-sided unless otherwise
noted. P-values of less than 0.05 are considered statisti-
cally significant.
Results
Criteria and categories for cytological
diagnosis
All 169 cytology specimens had adequate numbers of
epithelial cells to render a diagnosis. The first 28 cases
with matched surgical biopsy were used to set up the diag-
nostic criteria; the remaining 141 cases were diagnosed
blinded to patient information and surgical biopsy diagnosis.
Based on the morphology from our 28 cases with matched
cytology and biopsy, and previous esophageal cytology
classification systems,31,32 we developed a set of diagnostic
categories for glandular cells obtained by cytology (Table 1).
Analysis of cytological diagnosis
Table 2 compares the histopathological biopsy diagnosis to
the cytological diagnosis for the 141 cases that were diag-
nosed blindly. Five of 141 cases without matched surgical
Table 1 Diagnostic categories of esophageal glandular cells in EsophaCap cytology sample
Cytology categories Criteria for cytological diagnosis Matched
biopsy
Non-diagnostic (ND) Scant squamous cellularity, extensive bacteria or blood and poor preservation
No or rare columnar cell (NCC) Normal squamous cells with less than 4 groups glandular cells in cell block SE or sam-
ple error
Columnar cell with no goblet cell
(CCNGC)
Large flat, cohesive sheets of glandular cells with distinctly outlined, smooth, sharply
defined edges; uniform round or oval nuclei in the basal layer; MUC2 IHC negative
CM
Intestinal metaplasia with no high
grade dysplasia (IMNHGD)
Large flat sheets of cells with smooth, sharply defined edges and goblet cells; the uniform
round or oval nuclei in the basal layer or focal nuclear stratification and hyperchromasia;
goblet cells more ready present in cell block, positive for MUC2 IHC
IM; LGD;
ID
Atypical glandular cells (AGC) Small or large flat sheets of atypical gland cells with nuclear enlargement, uniform, promi-




Suspicious for EAC (SFEAC) Rare atypical cells with hyperchromasia, pleomorphism, prominent nucleoli, irregular
nuclear contour and thickened membrane, overlapping, loss of polarity, and rare atypical
mitoses
HGD/EAC
Esophageal adenocarcinoma (EAC) Small 3-dimensional clusters of atypical glandular cells with prominent nucleoli, irregular
nuclear contours, high N/C ratio, loss of polarity, hyperchromasia, pleomorphism, frequent
mitosis and focal necrosis (tumor diathesis), some atypical single cells
EAC
Abbreviations: IM, intestinal metaplasia; CM, columnar cell metaplasia; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; ID, indefinite dysplasia; LGD, low-
grade dysplasia; SE, squamous epithelium.
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biopsy diagnosis were excluded from the analysis. Of 136
cases, 34 cases were diagnosed as no columnar cell
(NCC). These Thin-Pap smears contained normal squa-
mous cells and no or rare glandular clusters (≤3 clusters)
(Figure 2A). Fifteen columnar cell with no-goblet cell
(CCNGC) cases contained predominant squamous cells
and some large, flat cohesive sheets of glands with hon-
eycomb pattern, smooth, sharp edge and small round or
oval nuclei (Figure 2A) and columnar cell glands without
goblet cells in cell block (Figure 2C) as well as negative
MUC2 IHC (Figure 2E).
Thirty-nine intestinal metaplasia with no high-grade
dysplasia (IMNHGD) cases consisted of large flat sheets
of cells with focal goblet cells and smooth, sharply defined
edges. The cytoplasm of goblet cells showed slightly
basophilic mucin. The nuclei were small, and linearly
arranged in the basal layer (Figure 2B), which could be
compatible with surgical biopsy IM cases. Some nuclei
showed focal nuclear stratification and hyperchromasia in
a honeycomb pattern, which could be compatible with
low-grade dysplasia (LGD) cases. However, the differen-
tiation of IM and LGD is thought not to be reliable in
esophageal cytology.31 Therefore, we combined these into
a single IMNHGD category. Goblet cells were not easily
identified in the smears but were readily identified in
corresponding cell blocks (Figure 2D) and by MUC2
IHC (Figure 2F).
Atypical glandular cells (AGC) consisted of small three-
dimensional clusters of atypical glandular cells with nuclear
enlargement, overlapping and hyperchromasia, prominent
nucleoli and smooth nuclear membrane (Figure 3A and
B). Cytoplasm showed decreased cytoplasmic mucin.
Suspicious for EAC (SFEAC) consisted of rare atypi-
cal cells with hyperchromasia, pleomorphism, prominent
nucleoli, irregular nuclear contour and thickened mem-
brane, overlapping, loss of polarity and rare mitosis
(Figure 3C and D). EAC had similar morphologic changes,
but abundant cells or clusters (Figure 3E and F). In addi-
tion, EAC consisted of frequent mitosis and focal necrosis
(tumor diathesis). Some single, loose tumor cells were
identified in EAC, but not in benign glands. One atypical
squamous cell (ASC) and one squamous cell carcinoma
(SCC) were diagnosed. The cytology showed high nuclear/
cytoplasm ratio, hyperchromatin, pleomorphic. However,
focal goblet cells were also identified in its cell block.
Estimation of glandular cell abundance
The number and percentage of glandular cell groups in cell
blocks were counted manually (Table 3). Thirty cases
(22%) had more than 30 glandular clusters. Almost half
of 136 cases (50%) had between 4 and 29 groups of
glandular cells. Fifty-one cases (37%) had ≤3 glandular
groups in cell blocks: 34 of 51 cases were diagnosed as
NCC; 17 had more glandular cells in cytology smear or
positive MUC2 immunostain in cell block to make diag-
nosis in glandular categories. The percentages of glandular
cells in cell blocks were also counted, and the range was
from 0.1% to 80%. The average of glandular cells
was 7.1%.
Evaluation of MUC2 IHC on TMA
MUC2 was reported as highly specific markers for goblet
cells metaplasia in distal esophagus and gastroesophageal
junction (GEJ).33 We further performed MUC2 IHC in
multiple cases of IM, CM, SE, LGD, HGD, and EAC on
TMA and evaluated its sensitivity and specificity for detec-
tion of IM and beyond in surgical specimens (Table 4 and
Figure 4). IM cases were 100% positive for MUC2 IHC but
Table 2 Number of surgical biopsy and cytology cases with each category
Biopsy Dx # Cases Cytology Dx # Cases
Esophageal adenocarcinoma 29 Esophageal adenocarcinoma 5
High grade dysplasia 20 Suspicious for EAC 7
Atypical glandular cells 34
Low grade dysplasia/indefinite dysplasia 18/1 Intestinal metaplasia with no high grade dysplasia (IMNHGD) 39
Intestinal metaplasia 55
Columnar cell metaplasia 7 Columnar cell with no goblet cell (CCNGC) 16
Squamous cell carcinoma 1 Squamous cell carcinoma 1
Squamous dysplasia 1 Atypical squamous cells 1
Squamous epithelium 4 Non-columnar cell metaplasia 34
Total 136 136
Abbreviation: EAC, esophageal adenocarcinoma.
Dovepress Zhou et al
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only positive in 50.5% of the cases of EAC. We calculated
sensitivity, specificity and accuracy in two ways. First, we
set BE as positive and CM, SE and SCC as negative. The
sensitivity and specificity and accuracy were 100%, 99.5%
and 99.5%. Second, we set IM, LGD, HGD and EAC as
positive and CM, SE and SCC as negative. The sensitivity
and specificity and accuracy were 66.9%, 99.5% and 83.4%
due to lower positive rate of EAC cases.
Combined EsophaCap cytology and MUC2 IHC for
screening for BE and beyond
For this phase of analysis, we asked how accurate com-
bined cytology and MUC2 IHC would be for screening IM
and beyond, in which the goal is to detect IM and more
advanced disease in a patient population. We defined
a “negative” biopsy as patients with surgical pathology
diagnoses of CM, SE, and a negative cytology diagnosis
as NCC, CCNGC in combination with a negative MUC2
IHC result. We defined a “positive” biopsy as IM, LGD,
HGD and EAC, and a positive cytology as IMNHGD,
AGC, SFEAC, EAC or any positive MUC2 IHC result.
By comparing the biopsy result to the cytological/IHC
diagnosis, we determined that the sensitivity, specificity and
accuracy for detecting IM and beyond were 67.77% (95%
CI: 58.67–75.98%), 90.91% (95% CI: 58.72–99.77%) and




Figure 2 Intestinal metaplasia with no high-grade dysplasia (IMNHGD) and columnar cell with no goblet cells (CCNGC) of EsophaCap samples. (A) CCNGC: The specimen
consists of multiple squamous cells and one sheet of glandular cells. The glandular cells are well organized. No goblet cells are identified. (B) IMNHGD: The specimen
consists of multiple sheets of glandular cells. The glandular cells are well organized. Focal goblet cells are present (arrowhead). (C and E) CCNGC: One columnar cell gland
is present in cell block. The columnar cells are negative for MUC2 immunostain; (D and F) IMNHGD: Goblet cells are present in cell block. The goblet cells and adjacent
columnar cells are positive for MUC2 immunostain.
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predictive value (PPV) and negative predictive value (NPV)
were 98.80% (95% CI: 92.65–99.81%) and 20.41% (95%
CI: 10.71–34.00%). MUC2 IHC alone had very high spe-
cificity to identify IM and beyond (100%), but reasonable
sensitivity (79.27%; 95% CI: 68.89–87.43%) if we only
calculate the cases with >4 groups of glandular cells in
cell blocks. If we count all cases regardless of cellularity,
the specificity to identify IM and beyond is 100%, but
sensitivity is 54.17% since glandular cells may or may not
present in cell blocks (sample error), combined with the
observation that dysplasia and EAC are often negative for
MUC2 IHC.
EsophaCap cytology for surveilling BE patients for
HGD and EAC
In the second phase of analysis, we divided the diagnostic




Figure 3 Atypical glandular cells (AGC), suspicious for esophageal adenocarcinoma (SFEAC) and esophageal adenocarcinoma (EAC). (A and B) AGC: The specimen consists
of a sheet of glandular cells with increased nuclear size and prominent nucleoli (see arrow). (C and D) SFEAC: The specimen consists of rare cluster of glandular cells with
high nuclei/cytoplasm ration, irregular nuclear contour, prominent nucleoli, hyperchromasia and overlapping. (E and F) EAC: The specimen consists of multiple clusters of
glandular cells with high nuclei/cytoplasm ration, prominent nucleoli, irregular nuclear contour, hyperchromasia, mitosis (see arrowhead), overlapping and the single cells.
Table 3 Number of glandular cell (GC) clusters in cell block
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surveillance test designed to identify the presence of HGD or
EAC in a population of patients with known IM. We defined
a “negative” biopsy as one of CM, SE, IM and LGD, and
a “positive” biopsy as HGD or EAC. We defined a negative
cytology as one showing NCC, CCNGC and IMNHGD, and
a positive cytology as AGC, SFEAC or EAC. The sensitivity,
specificity and accuracy of the cytological diagnosis for
distinguishing negative from positive biopsies were 40.43%
(95% CI: 26.37–55.73%), 71.76% (95% CI: 60.96–81.00%)
and 60.60% (95%CI: 51.70–69.00%), respectively. The PPV
and NPV were 44.19% (95% CI: 32.77–56.25%) and
68.54% (95% CI: 62.43–74.06%).
Discussion
In the present study, we used paired biopsy and cytology
specimens gathered from a cohort of 169 patients to inves-
tigate the potential utility of the EsophaCap swallowable
encapsulated cytology sponge for IM screening, as well as
for the surveillance of IM patients for progression to HGD
and EAC. In the IM screening context, we found that with
the combined cytology and MUC2 IHC, the sensitivity,
specificity and accuracy for detecting IM and beyond were
67.77%, 90.91% and 69.70, respectively. In the IM pro-
gression surveillance context, we were able to identify
HGD/EAC with a sensitivity of 40% and a specificity
of 71%.
Cytological examination of esophageal cells has been
used for screening and early detection of esophageal car-
cinoma in many countries including China,19–22 South
Africa,34 United States,22–24 Britain,34 Iran35 and
Switzerland.28 Application of a sponge-on-a-string for
cytology sample collection from esophagus was reported
in several studies.25,26,29,34 The Cytosponge(™) has been
heavily studied as a tool for non-endoscopic diagnosis of
BE.25–27 Using TFF3 immunostain in cell blocks, the over-
all sensitivity of the test for BE was 79.9%, increasing to
87.2% for patients with ≥3 cm of circumferential BE.25,26
In our study, we used EsophaCap to collect esophageal
samples. We focused on screening IM and beyond instead
of IM only. The sensitivity is 68% relatively low for
diagnosing IM and beyond, but the specificity is 91%,
relatively high. A lower level of sensitivity is probably
due to the scant cellularity from some EsophaCap samples.
Fifty-one cases (37%) had ≤3 glandular groups in cell
blocks. Further improvement of the EsophaCap sampling
could increase the sensitivity of this test. The Pap smear as
a cervical cancer screening test is one of the most success-
ful cancer screening tests with pooled sensitivity and spe-
cificity as 43–84% and 88–95% and HPV test has 58–94%
sensitivity and 88–90% specificity.36–38 Our result has
similar range of the sensitivity and specificity to screen
IM and beyond compared to Pap smear and HPV tests for
cervical cancer,37 which indicate that the EsophaCap com-
bined with MUC2 IHC is a potentially good screening
approach for IM and beyond.
A central aim of the current study was to establish mor-
phological criteria for evaluating cytology obtained using the
EsophaCap (™) swallowable encapsulated sponge.
A challenge in interpreting the cytology is that the sponge
almost certainly samples some gastric epithelium from the
GE junction before its passage through the esophagus.
However, neither cytology nor histology can differentiate
columnar cells originating in the stomach from columnar
cell metaplasia in the esophagus. Therefore, we require the
presence of goblet cells to diagnose IM and prefer to use
terms such as columnar cells with no goblet cell metaplasia
(CCNGC) to describe MUC2 negative glandular cells.
Another challenge is the differentiation of inflammation-
related reactive atypia in columnar cell metaplasia and IM
from HGD and EAC. We created a category of “atypical
glandular cells” (AGC) to fit these cases (Table 1). However,
11 of 36 cytological cases called AGC had corresponding
biopsies diagnosed as HGD or EAC. Therefore, we included
AGC among the classes of “positives”.
The diagnosis of LGD in biopsy tissues has high inter-
observer variability,38,39 and the diagnosis of LGD in
esophageal cytology from brushing and ballooning is












Adenocarcinoma 109 55 (50.5%) 54 (49.5%)
High-grade
dysplasia
8 8 (100%) 0 (0%)
Low-grade
dysplasia
31 25 (80.7%) 6 (19.3%)
Intestinal
metaplasia
33 33 (100%) 0 (0%)
Columnar cell
metaplasia
64 1 (1.6%) 185 (98.4%)
Squamous
epithelium
95 0 (0%) 95 (100%)
Squamous cell
carcinoma
27 0 (0%) 27 (100%)
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even more of a challenge.31,32,40 Three studies have
reported that the sensitivities for detection of LGD in
esophageal cytology range from 20% to 31%.31,32,40 In
our study, we confirmed that it was difficult to identify
LGD in Thin Pap smear and cell blocks. Therefore, we
created the cytological category “intestinal metaplasia with
no high-grade dysplasia” (IMNHGD) which includes spe-
cimens suspicious for low-grade dysplasia as well as IM.
Cytology diagnosed as IMNHGD were concordant with
a histological diagnosis of IM and LGD in 27(69.23%) of
39 cases; nevertheless the matched biopsy of these cases
showed HGD in 6/39 (15.38%) cases and EAC in 6/39
(15.38%) of cases. The morphology criteria for IMNHGD
may need to be made more stringent in order to further
reduce miscalling of HGD and EAC.
The cytological criteria for “EAC” are abundant
obvious malignant cells with focal necrosis (tumor dia-
thesis) and atypical single cells. The criteria of “suspi-
cious for adenocarcinoma” (SEAC) is similar to EAC,
but with scant cellularity and without necrosis. The
sensitivity for the cytological diagnosis of HGD/EAC
in esophageal brushing/ballooning in most studies
ranges from 82% to 100%.31,32,40 In contrast, our
observed sensitivity of 40% is much lower compared
to most studies. The major problem is the lower cellu-
larity in our study. As high as 37% (18/49) of HGD and
EAC cases showed only 0–3 glandular groups in cell
blocks, which presented difficulties in making definite
cytological diagnosis. As we mentioned before, the




Figure 4 MUC2 immunohistochemical study (IHC) in esophageal tissue microarray (TMA). (A) Columnar cell metaplasia with negative MUC2 immunostain; (B) Barrett’s
esophagus with positive MUC2 immunostain; (C) Low-grade dysplasia with positive MUC2 immunostain; (D) High-grade dysplasia with positive MUC2 immunostain; (E)
Esophageal adenocarcinoma with negative MUC2 immunostain; (F) Esophageal adenocarcinoma with positive MUC2 immunostain.
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challenge for increasing the sensitivity of current tests.
The cytological studies reporting greatest sensitivity
uniformly used visually guided endoscopic brushings
to collect the cytological samples. However, the need
for endoscopy increases the cost and decreases the
convenience of the test compared to the swallowable
encapsulated sponge.
The patients in our study were from gastroenterological
clinics, which is not representative of population scenario.
The analysis of sensitivity and specificity also is limited
since our patients are at high risk for BE or dysplasia. In
future, we will screen the people in our population with
several risk factors such as over 50-year-old, obese,
GERD, smoking or alcoholic. Then, we can decide the
sensitivity and specificity of our new method to screen the
population.
Conclusion
Combining EsophaCap (™) cytology with MUC2
immunohistochemistry has reasonable sensitivity and
specificity for screening IM and beyond. However,
the EsophaCap has low to moderate accuracy for detec-
tion of HGD and EAC, and would be unsuitable for use
in a surveillance setting. In the future, combining
cytology, MUC2 IHC and molecular (eg, genetic)
tests may improve the accuracy for surveilling high-
risk patients for HGD and EAC. In addition, improving
EsophaCap sampling would also improve sensitivity
and specificity.
Abbreviation list
AGC, atypical glandular cells; CCNGC, columnar cell
with no goblet cell; CM, columnar metaplasia; EAC,
esophageal adenocarcinoma; HGD, high-grade dyspla-
sia; ID, indefinite dysplasia; IHC, immunohistochemis-
try; IM, intestinal metaplasia; IMNHGD, intestinal
metaplasia with no high-grade dysplasia; LGD, low-
grade dysplasia; NCC, no or rare columnar cell; ND,
non-diagnostic; SFEAC, suspicious for esophageal
adenocarcinoma.
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